Primary Amyloidosis with Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center
Outcomes in primary amyloid renal patients are of interest as the era of monoclonal antibody therapies begins. We studied 77 consecutive primary amyloid renal patients (58% men) for renal progression (ESRD), renal response (RR) and overall survival (OS). At diagnosis median age was 63 (range, 35-81), eGFR 70ml/min (5-114), dFLC 127mg/L (1-9957), ESRD 4%, renal stage 2 and 3 78%, and cardiac stage 2 and 3 56%. Ninety-six percent received bortezomib and 44% both stem cell transplant (SCT) and bortezomib, 68% achieved complete or very good partial hematologic responses (CR/VGPR), 34% had ESRD and 39% RR.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Sandy W. Wong, Denis Toskic, Melissa Warner, Cindy Varga, Alejandro Moreno-koehler, Daniel Fein, Teresa Fogaren, Lisa Lee, Colin M. Oliver, Spencer D. Guthrie, Raymond L. Comenzo Tags: Original Study Source Type: research
More News: Amyloidosis | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants | Velcade